Companies ›Consumer Non Cyclicals ›GXH.NZ

GXH.NZ — NZX Drug Retailers

Green Cross Health Ltd

$1,49

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

5,43 %

Op margin

7,4 %

ROE

9,6 %

Net margin

3,1 %

Debt / equity

0,81

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Green Cross Health Ltd operates as a drug retailer in the Food & Drug Retailing industry, generating revenue primarily through the sale of pharmaceuticals and health-related products.

Business. Green Cross Health Ltd (GXH.NZ) is a drug retailer operating within the Food & Drug Retailing industry. The company generates revenue through the sale of products and is headquartered in New Zealand. It is primarily listed on the New Zealand Exchange (NZX). Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %

SectorConsumer Non-Cyclicals

Business sectorFood & Drug Retailing

IndustryDrug Retailers

ActivityFood & Drug Retailing

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

9,6 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning GXH.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to GXH.NZ. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Green Cross Health Ltd (GXH.NZ) is a drug retailer operating within the Food & Drug Retailing industry. The company generates revenue through the sale of products and is headquartered in New Zealand. It is primarily listed on the New Zealand Exchange (NZX). Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %

SectorConsumer Non-Cyclicals

Business sectorFood & Drug Retailing

IndustryDrug Retailers

ActivityFood & Drug Retailing

AI synthesis

GENERATED

Green Cross Health Ltd maintains a debt-to-equity ratio of 0.81, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is characterized as medium risk, with a current ratio of 0.97, suggesting limited short-term liquidity cushion. Free cash flow of NZD 27.78 million supports operational flexibility, though capital expenditures of NZD 5.84 million reflect ongoing investment in infrastructure.

Profitability metrics show a return on equity of 9.59% and a return on assets of 4.14%, both below the industry median for Drug Retailers. The operating margin of 7.4% (NZD 38.72 million operating income on NZD 523.76 million revenue) lags behind the sector average, indicating potential inefficiencies in cost management or pricing power.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of segmentation exposes Green Cross Health Ltd to localized demand shocks and regulatory risks. No material international revenue is reported, suggesting a domestic New Zealand focus.

Revenue growth has been modest, with actual revenue of NZD 568.53 million trailing the NZD 523.76 million reported in the latest financial snapshot. Analysts project continued low-growth dynamics, with no material acceleration in revenue or margin expansion expected in the next fiscal year.

Risk factors include a negative net cash position after subtracting total debt, which elevates liquidity risk. Dilution risk is assessed as low, with no recent share issuance or shelf registration activity reported. However, the company's NZD 135.17 million in long-term debt could constrain financial flexibility during periods of economic stress.

Recent filings and transcripts show no material changes in strategic direction or capital structure. The company remains focused on its core drug retailing operations, with no disclosed M&A activity or new market entry plans. No material regulatory or litigation risks are highlighted in the latest disclosures.

Key takeaways

Green Cross Health Ltd operates with a moderate debt load but faces liquidity constraints due to a current ratio below 1.
Profitability metrics lag behind industry medians, suggesting operational inefficiencies or pricing pressures.
Revenue concentration in a single segment and geographic market increases vulnerability to localized risks.
Free cash flow remains positive, but capital expenditures and debt servicing obligations limit reinvestment capacity.
No material dilution risk is currently present, though liquidity risk remains elevated.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$1,49

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$166.6M

Net cashⓘ

-$109.0M

Current ratioⓘ

1.0

Debt / equityⓘ

0.8

ROAⓘ

4.1%

ROEⓘ

9.6%

Cash conversionⓘ

330.0%

CapEx / revenueⓘ

-1.1%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin7,4 %Best in class

Net Margin3,0 %Above P75

ROE9,6 %Above P75

Capex / Rev-1,1 %Above median

D/E0,81Below median

Cash Conv3,30Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Green Cross Health Ltd Market data — financials · 2026-05-28
Green Cross Health Ltd Market data — analyst estimates · 2026-05-28

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

GXH.NZCanonical

NZX · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread